PleoPharma is a privately held neuropsychiatric and addiction-focused drug developer headquartered in Phoenixville, Pennsylvania. Its lead asset, PP-01, is a dual-mechanism oral therapy that targets suppressed CB1 receptors and neurotransmitter dysregulation in the mesolimbic reward pathway. PP-01 is the only FDA Fast Track-designated treatment for mitigating cannabis withdrawal symptoms and is now advancing into Phase 3 trials. The company’s mission addresses a large, underserved population: SAMHSA data show roughly 20.6 million Americans had Cannabis Use Disorder in 2024, with treatment incidence growing 27 % annually from 2018–2023. Proceeds from recent financing will fund the Phase 3 program, positioning PP-01 to become a first-in-class solution if approved. PleoPharma’s management and board have collectively overseen more than 50 product approvals and 100 INDs, supporting a track record of value creation. No commercial revenue has been disclosed; the firm remains pre-approval and reliant on venture funding to advance clinical development.

Total raised

$36M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2025